



**EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

**MINUTES OF THE MEETING HELD ON WEDNESDAY 21st AUGUST 2019 AT
12.30pm**

**IN SEMINAR ROOM 2, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL**

PRESENT:

Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Acting Chair)
Mrs C Woffindin (CW) Mr V Goodey (VG)	Medicines Information Manager, ELHT Assistant Director of Pharmacy, Clin Service ELHT
Mr J Vaughan (JV) Dr S Jackson (SJ) Dr K Burch (KB) Mr A Gray (AG) Mr U Akram	Commissioning Support Pharmacist NHS EL/BwD Clinical Commissioning Group MM Lead, GP EL Consultant Microbiologist ELHT Clinical Pharmacist, ELHT Pharmacist, Lancashire Care Foundation Trust

2019/089: APOLOGIES:

Dr D Gavan (DG)	Consultant Radiologist ELHT
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Dr T Mackenzie (TM)	GP, EL CCG

2019/090: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2019/091: MINUTES OF JUNE MEETING:

Accepted as a correct record.

2019/092: MATTERS ARISING:

2019/044: LMMG Recommendations (From Feb LMMG) - Out of Area Prescribing Position Statement – local simplified version presented. To add a footnote to statement 'item not on local formulary' to state 'for commonly used medications eg Ace inhibitors/ eye drops' use discretion. Approved for use and upload to website once updated as above.

2019/064: Formulary Updates - Tranexamic acid injection for topical use – SJ has not yet had a response from tissue viability / lead district nurse re writing a procedure to support its use. Some guidelines from other trusts located. VG to ask palliative care if tranexamic acid topical use can be included in local palliative care guideline

ACTION: SJ to follow up with Tissue Viability Nurse and VG to follow up with palliative care clinicians.

2019/080: Contract Agreements – Impact across ICP- meeting to be arranged.

2019/093: NEW PRODUCT REQUEST – LANREOTIDE for patients with HEREDITARY HAEMORRHAGIC TELANGIECTASIA

Lanreotide requested by Dr J Collum, Consultant Gastroenterologist & IBD service lead, for treatment of recurrent gastrointestinal blood loss due to hereditary haemorrhagic telangiectasia (HHT) (unlicensed indication). In the small studies included with application the patients and indication were different to the situation requested.

Lanreotide may be clinically appropriate for the patient concerned so treatment could be tried, within the trust (director need to agree to fund) to see if it helps and an individual funding request (IFR) application is recommended for continuation if required. It will not be included on the formulary.

Resolved: Lanreotide for HHT recommended as an Individual Funding Request if ongoing use required. Not included on formulary.

2019/094: NEW PRODUCT REQUEST – BIOXTRA® SALIVA REPLACEMENT GEL

BioXtra® saliva replacement gel requested by Mr D Moore, Consultant in Restorative Dentistry, for xerostomia caused by radiation to oral cavity when other treatments have been insufficient. This product offers longer relief with less frequent applications required.

It was agreed to add to formulary, with amber traffic light, as additional saliva replacement gel for patients who have had radiation to oral cavity.

Resolved: BioXtra® oral gel added to formulary for patients who have had radiotherapy to oral cavity. Traffic Light: AMBER

2019/095: NEW PRODUCT REQUEST – PENTOSAN POLYSULFATE (ELMIRON®)

Pentosan polysulfate (Elmiron®) requested by Urology Consultants for treatment of Bladder pain syndrome / Interstitial cystitis as an oral option. The evidence for use is limited. In an evidence review from NICE in 2015, a RCT from 2014 found no difference to placebo, and other trials have used inconsistent methods. There is a NICE technology appraisal for pentosan polysulfate for interstitial cystitis due in November 2019, therefore ELMMB will await the NICE guidance before formulary decision is made.

Resolved: Decision on Pentosan Polysulfate (Elmiron®) to await NICE guidance.

2019/096: NEW PRODUCT REQUEST – PARATHYROID HORMONE (NATPAR[®])

Parathyroid Hormone (Natpar[®]) is requested by Dr Ramtoola, Consultant Endocrinologist, for adjunctive treatment of chronic hypoparathyroidism not adequately controlled with standard therapy. A review of parathyroid hormone by NICE was suspended in 2018 and the SMC have not recommended its use. Suggest it is referred to LMMG for a full evidence review.

ACTION: CW to forward application to LMMG for full evidence review

2019/097: LMMG CONSULTATIONS (for Sept LMMG)

Dymista New Medicine Assessment – ELMMB has a concern that the evidence for use of Dymista is weak and based on comparison to placebo or monotherapy. The ingredients (corticosteroids and antihistamines) are available as separate products and support NHS England self-care. Combination products are not usually supported by LMMG. Suggest Black traffic light.

Psoriasis Biologic Treatment Pathway - updated – new products have been included. Update is supported by ELMMB.

Ustekinumab for Crohn's – Alternate Dosing Intervals – it is not clear that the recommendation is to include the option to reduce the dosing interval to 4 weekly. Reference to unlicensed use should be clear near the top of the recommendation.

Rheumatoid Arthritis Biologics Pathway - updated – supported by ELMMB.

Ciclosporin (Verkasia) Eye Drops New Medicines Assessment – supported by ELMMB with the request to include how often a specialist review is required.

Brivaracetam Assessment – updated for children – ELMMB support the addition of children to the existing assessment and the traffic light change to amber.

Guidelines for the Home Monitoring of Blood Glucose – updated - comments are on page 5, paragraph starting 'However' - suggest the words 'at least one fewer box of test strips to be prescribed per month' be put in bold. CCGs are currently reviewing local blood glucose monitoring guidance and will include discussion on this guidance.

Combined Adult & Children ADHD Shared Care Guideline – LCFT revision – supported by ELMMB.

Vitamin D Position Statement – Comments are in Recommendations box suggest removing some words to simplify the statements: 1st paragraph - remove 'high risk' and leave as 'and insufficiency in symptomatic patients' 2nd paragraph - remove 'for symptomatic individuals that are at high or normal risk of Vitamin D deficiency' 3rd paragraph - remove 'Asymptomatic' and 'high or normal' to leave as 'Patients that are at risk of Vitamin D deficiency ..' For the Black recommendations - add 'except for the following groups: elderly, in a care home, children, pregnant.'

Resolved: Comments to be sent to LMMG

2019/098: LMMG Recommendations (From June LMMG)

Prasterone Recommendation – not recommended for use accepted as written for ELHE. **Traffic light: BLACK**

Clopidogrel Patient Information Leaflet – updated - accepted as written for use in ELHE.

Insulin Toujeo Information Sheet - updated – acknowledged by ELMMB. LR/JV will prepare a simplified version on one page for use in ELHE for next meeting.
ACTION: JV/LR to produce simplified version.

Guidelines for the Prescribing of Nutritional Supplements Post Bariatric Surgery – updated – the third paragraph in recommendations box is not correct. Specific comments to be sent to LMMG. Local guideline to be reviewed and potentially add the top two statements from recommendation box to local guideline.
ACTION: JV/LR to send comments to LMMG and review local ELHE guideline.

Riluzole Shared Care Guideline – updated – the primary care responsibility point 8, febrile illness should be worded the same as adverse effects information on febrile illness. Request LMMG to amend.
ACTION: JV/LR to request LMMG to amend

2019/099: LMMG Recommendations (From July LMMG)

Brivaracetam Recommendation – for use in children accepted as written for use in ELHE. **Traffic Light: Amber**

Aliskiren change to Black Traffic Light – in line with NHSE low priority prescribing commissioning guidance. Accepted for ELHE. **Traffic light: BLACK**

Minocycline change to Black Traffic Light – in line with NHSE low priority prescribing commissioning guidance. Accepted for ELHE. **Traffic light: BLACK**

Trans Male & Trans Female Hormone Therapy in Gender Dysphoria Prescribing Information Sheets – acknowledged, add to website.

Chronic non-cancer Pain Guidelines – updated – accepted as written for ELHE.

Testosterone Shared Care Guideline – updated – comment that monitoring information on page 5 should include that the testosterone should be an early morning fasting sample as on local flow chart. Request LMMG to amend.

2019/107: Adult Male Testosterone Guidance for Primary Care

ELHT flow chart with guidance for primary care for adult male testosterone blood level testing (including specifying a morning fasting sample) is accepted for use in ELHE.
Resolved: Adult Male Testosterone Guidance for Primary Care accepted for use.

2019/100: FORMULARY UPDATES

Olaratumab – withdrawn from market, remove from formulary.

Co-Danthrusate capsules – discontinued, remove from formulary.

Ranolazine – request to change to green traffic light. GPs do not consider it is appropriate for initiation in primary care. To remain Amber traffic light.

Rosuvastatin – added to formulary as a second line option in patients with a higher cardiovascular risk.

Resolved: Formulary to be updated as above

2019/101: ELHT ANTIMICROBIAL GUIDE - UPDATES

Colistin – intravenous dosing guideline added

Amikacin – intravenous dosing guideline added

Maxillofacial – severe skin infections updated

Acute prostatitis – guidelines updated in line with NICE

Chemoembolisation (TACE) prophylaxis - updated

Resolved: Antimicrobial Guide new & updated sections accepted for formulary

2019/102: CONTINENCE AND CATHETER CARE FORMULARY - UPDATED

Updated descriptions and some new products included in updated formulary. Continence & Catheter Care formulary approved.

Resolved: Continence & Catheter Care formulary approved.

2019/103: RMOG Guidance

Prescribing of liothyronine – updated – prescribing guidance for liothyronine has been updated. Acknowledged – traffic light to remain BLACK

Resolved: RMOG: Updated Prescribing of Liothyronine guidance acknowledged.

2019/104: MONITORING REQUIREMENTS OF HIGH RISK DRUGS IN PRIMARY CARE

The monitoring requirements of high risk drugs in primary care has been updated. Acknowledged by ELMMB

Resolved: Updated Monitoring Requirements of High Risk Drugs acknowledged.

2019/105: NHSE LOW PRIORITY PRESCRIBING COMMISSIONING GUIDANCE

Deferred to next meeting

2019/106: HOSPITAL ADMISSIONS CHECKLIST - UPDATED

Deferred to next meeting

2019/108: NHSE STANDARD GMS CONTRACT 2019 – EXCESSIVE PRESCRIBING

Deferred to next meeting

2019/109: LANCASHIRE CARE SUBCUTANEOUS SYRINGE PUMP PROTOCOL - UPDATE

Deferred to next meeting

2019/110: NICE RECOMMENDATIONS (from June)

Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes [TA583] is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned

Traffic Light: GREEN

Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer [TA584] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Ocrelizumab for treating primary progressive multiple sclerosis (TA585) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322 updated) is recommended as an option by NICE. Approved in line with NICE.

Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies (TA171 updated) is recommended as an option by NICE. Approved in line with NICE.

2019/111: NICE RECOMMENDATIONS (from July)

Nusinersen for treating spinal muscular atrophy [TA588] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity [TA589] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

2019/112: NICE RECOMMENDATIONS (August Fast Track)

Risankizumab for treating moderate to severe plaque psoriasis (TA596) is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned

Traffic Light: RED

2019/113: NICE HIGHLY SPECIALISED TECHNOLOGY (HST) GUIDANCE

Inotersen for treating hereditary transthyretin amyloidosis (HST9) - May 2019

Burosumab for treating X-linked hypophosphataemia in children and young people (HST8) - October 2018

Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7) - February 2018

Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6) - August 2017

Eliglustat for treating type 1 Gaucher disease (HST5) - June 2017

Migalastat for treating Fabry disease (HST4) - February 2017

Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3) - July 2016

Elosulfase alfa for treating mucopolysaccharidosis type IVa (HST2) - December 2015

Eculizumab for treating atypical haemolytic uraemic syndrome (HST1) - January 2015

Resolved: All HST guidance acknowledged.

2019/114: EAMS

Polatuzumab vedotin in combination with bendamustine and rituximab is indicated for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in adult patients who are not eligible for hematopoietic stem cell transplant.

Avelumab in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

STANDING ITEMS

2019/115: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – June 2019

Minutes acknowledged

2019/116: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – July 2019

Minutes acknowledged

2019/117: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – May 2019

Minutes acknowledged

2019/118: FOR ACTION/INFORMATION: LANCASHIRE CARE FT D & T MINUTES – July 2019

Minutes acknowledged

DATE OF NEXT MEETING – Wednesday 18th September 2019 12.30pm, Seminar Room 2, Learning & Development Centre, RBH.

Please note meetings have reverted back to 12.30pm – 2pm

Dates for 2019: All 3rd Wednesday of the month starting at 12.30pm

18th September

16th October

20th November

18th December

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 21st AUGUST 2019

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2019/064	Formulary Updates – Tranexamic acid – awaiting procedure to support green traffic light	SJ	Aug 19
	Check if it can be included in palliative care guideline	VG	Sept 19
2019/095	New Product Request – Parathyroid Hormone (Natpar[®]) – send to LMMG for full evidence review	CW	Sept 19
2019/098	LMMG Recommendations (From June LMMG)		
	Insulin Toujeo Information Sheet – updated – simplified one page version to be produced for ELHE	JV	Sept 19
	Guidelines for the Prescribing of Nutritional Supplements Post Bariatric Surgery – comments to LMMG and local guideline to be reviewed	LR	Sept 19
	Riluzole Shared Care Guideline – request LMMG to review febrile illness wording	JV LR	Sept 19 Sept 19
2019/099	LMMG Recommendations (From July LMMG) Testosterone Shared Care Guideline – request LMMG add ‘fasting’ to the blood sample information	LR	Sept